News

Alkem Laboratories rises on signing licensing agreement with Sonnet BioTherapeutics Holdings Alkem Laboratories is currently trading at Rs. 6213.50, up by 77.50 points or 1.26% from its previous closing of Rs. 6136.00 on the BSE. The scrip opened at Rs. 6160.00 and has touched a high and low of Rs. 6222.45 and Rs. 6136.80 respectively. So far 686 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 6440.00 on 17-Sep-2024 and a 52 week low of Rs. 3509.60 on 26-Oct-2023. Last one week high and low of the scrip...
Alkem Laboratories rises on signing licensing agreement with Sonnet BioTherapeutics Holdings
Alkem Laboratories rises on signing licensing agreement with Sonnet BioTherapeutics Holdings
Source: Accord Fintech
2024-10-11 02:44:22 pm
Alkem Laboratories trades higher on signing patent licensing agreement with Takeda Pharmaceutical Company Alkem Laboratories is currently trading at Rs. 6105.00, up by 31.15 points or 0.51% from its previous closing of Rs. 6073.85 on the BSE. The scrip opened at Rs. 6030.55 and has touched a high and low of Rs. 6168.45 and Rs. 6030.55 respectively. So far 2769 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 6203.10 on 30-Aug-2024 and a 52 week low of Rs. 3440.05 on 05-Oct-2023. Last one week high and low of the scri...
Alkem Laboratories trades higher on signing patent licensing agreement with Takeda Pharmaceutical Company
Alkem Laboratories trades higher on signing patent licensing agreement with Takeda Pharmaceutical Company
Source: Accord Fintech
2024-09-03 04:29:05 pm
Buy Alkem Labs Ltd For Target Rs.6,234 By Choice Broking Ltd Alkem reported revenue below our estimations, however earnings were above our estimate. Revenue increased marginally by 2.2% YoY and 3.3% QoQ to INR 30,318mn. EBITDA at INR 6,086mn saw a good growth of 56.4% YoY and 51.4% QoQ. Margins expanded by 696bps YoY and 638bps QoQ to 20.1%. Adj. PAT saw a robust growth of 88.1% YoY and 77.4% QoQ at INR 5,393mn. The company expects to grow top-line inline with the industry growth of 10%, majorly driven by the domestic market. * India Business: The I...
Buy Alkem Labs Ltd For Target Rs.6,234 By Choice Broking Ltd
Buy Alkem Labs Ltd For Target Rs.6,234 By Choice Broking Ltd
Source: Choice Broking Ltd
2024-08-13 04:47:46 pm
Neutral Alkem Laboratories Ltd For Target Rs. 5,390 By Motilal Oswal Financial Services Exports growth offset by weak India business Increasing investments in the biosimilars segment *Alkem Lab (ALKEM) delivered a miss on 4QFY24 earnings, led by lower domestic formulation (DF) sales and higher R&D spend. Having said this, compared to earnings decline over FY22-23, it has delivered a 50% YoY earnings growth in FY24. This is largely on the back of lower raw material cost and reduced intensity of price erosion in the US generics segment. *We reduce our earnings estima...
Neutral Alkem Laboratories Ltd For Target Rs. 5,390 By Motilal Oswal Financial Services
Neutral Alkem Laboratories Ltd For Target Rs. 5,390 By Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services
2024-07-02 03:25:42 pm
Neutral Alkem Ltd For Target Rs.5,160 - Motilal Oswal Financial Services Focus remains on DF/US; valuations priced in * ALKEM is one of the pharmaceutical companies with the highest proportion of (66% of total sales 9MFY24) sales from the domestic formulation (DF) segment. * While it continues to outperform the industry in the DF segment, the outlook is dependent on the variability of season and acute infections as it derives 82% of DF sales from acute therapies. * After muted performance in the US generics business (23% of sales) over FY18- 23, there has...
Neutral Alkem Ltd For Target Rs.5,160 - Motilal Oswal Financial Services
Neutral Alkem Ltd For Target Rs.5,160 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services Ltd
2024-05-25 11:35:43 am
Add Alkem Labs Ltd For Target Rs. 5,668 - Choice Broking Alkem lab’s earnings were in line with our expectations on revenue front while EBITDA and PAT exceeded our expectations. Revenue at INR 33,2369mn saw a growth of 9.3% YoY owever declined by 3.4% sequentially. EBITDA saw a growth of 18.1% YoY and degrowth of 5.2% QoQ to INR 7,076mn with margin expansion of 159bps YoY to 21.3%. APAT at INR 6,423mn saw a massive growth of 41.3% YoY but degrew 4.9% QoQ. Company’s domestic business outperformed IPM by 200bps mainly on account of gastro...
Add Alkem Labs Ltd For Target Rs. 5,668 - Choice Broking
Add Alkem Labs Ltd For Target Rs. 5,668 - Choice Broking
Source: Choice Broking
2024-02-21 11:53:14 am
Reduce Alkem Labs Ltd For Target Rs.3,770 - Yes Securities US persistence drives beat; upgrade to Reduce Result Synopsis Prima facie Alkem reported better than ours/consensus expectation, but we note few points 1) US must have drove significant part of margin beat (on back of 20% QoQ growth) as pricing environment remains benign 2) no positive surprises in domestic business as weak acute season took its toll 3) Ex-R&D, other expenses still up 13% YoY and management has indicated no further cost savings likely. H2 margin has been indicated a...
Reduce Alkem Labs Ltd For Target Rs.3,770 - Yes Securities
Reduce Alkem Labs Ltd For Target Rs.3,770 - Yes Securities
Source: Yes Securities Ltd
2023-12-15 12:15:18 pm
Alkem Laboratories trades higher on the BSE Alkem Laboratories is currently trading at Rs. 3562.05, up by 17.30 points or 0.49% from its previous closing of Rs. 3544.75 on the BSE.The scrip opened at Rs. 3541.05 and has touched a high and low of Rs. 3569.90 and Rs. 3514.50 respectively. So far 1044 shares were traded on the counter.The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 4270.95 on 10-Aug-2023 and a 52 week low of Rs. 2835.05 on 02-Mar-2023.Last one week high and low of the scrip stood at Rs. 3705....
Alkem Laboratories trades higher on the BSE
Alkem Laboratories trades higher on the BSE
Source: Accord Fintech
2023-09-25 12:15:04 pm